Exogenous Progesterone Increases Nuchal Translucency

This article originally appeared here.
Share this content:
Exogenous Progesterone Increases Nuchal Translucency
Exogenous Progesterone Increases Nuchal Translucency

TUESDAY, March 31, 2015 (HealthDay News) -- Exogenous progesterone seems to increase nuchal translucency (NT), according to a study published in the March issue of the American Journal of Obstetrics & Gynecology.

Noting that progesterone could lead to abnormal blood flow patterns and subsequently to increased NT, Claudio Giorlandino, M.D., from the Campus Bio Medico University of Rome, and colleagues examined the effects of endogenous progesterone on NT thickness. Data were included for 3,716 women who came to measure NT between 11 and 14 weeks of gestation, who were classified into two groups: women receiving exogenous progesterone and controls. Three NT scans were performed for each case.

In a crude analysis, the researchers found that NT increased in the exogenous progesterone group (P < 0.05). In the group at low risk for fetal aneuploidies, the same results were obtained (P < 0.05). Correlations between altered NT and gestational age (P < 0.0001) and progesterone exposure (P < 0.05) were confirmed in a factorial analysis of variance model. No significant differences were seen in subgroup analysis of the characteristics of treatment (route, formulation, and dose).

"We demonstrate that exogenous progesterone significantly increases NT thickness when compared with controls," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Social, Communication Delays With False-Negative on M-CHAT

Social, Communication Delays With False-Negative on M-CHAT

Delays for those who pass M-CHAT screening at 18 months but are later diagnosed with ASD

FDA Approves Aimovig to Prevent Migraines

FDA Approves Aimovig to Prevent Migraines

Patients taking Aimovig reported one to two fewer monthly migraine days than those taking pacebo

Risk of Dementia Up for Older Adults With Lowest Wealth

Risk of Dementia Up for Older Adults With ...

Increased risk seen independent of education, index of multiple deprivation, health indicators

is free, fast, and customized just for you!

Already a member?

Sign In Now »